Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Accelerated access to innovative medicines for patients in need.

Baird LG, Banken R, Eichler HG, Kristensen FB, Lee DK, Lim JC, Lim R, Longson C, Pezalla E, Salmonson T, Samaha D, Tunis S, Woodcock J, Hirsch G.

Clin Pharmacol Ther. 2014 Nov;96(5):559-71. doi: 10.1038/clpt.2014.145. Epub 2014 Jul 9.

PMID:
25006877
2.

Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?

Degrassat-Théas A, Paubel P, Parent de Curzon O, Le Pen C, Sinègre M.

Pharmacoeconomics. 2013 Apr;31(4):335-43. doi: 10.1007/s40273-013-0039-4.

PMID:
23529210
3.

Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.

Leyens L, Brand A.

Public Health Genomics. 2016;19(3):187-91. doi: 10.1159/000446537. Epub 2016 Jun 1.

4.

Drug reimbursement policies in Canada--need for improved access to critical therapies.

LeLorier J, Bell A, Bougher DJ, Cox JL, Turpie AG.

Ann Pharmacother. 2008 Jun;42(6):869-73. doi: 10.1345/aph.1K373. Epub 2008 May 13.

PMID:
18477735
5.

Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?

Wonder M, Backhouse ME, Sullivan SD.

Value Health. 2012 May;15(3):586-90. doi: 10.1016/j.jval.2012.02.004. Epub 2012 Apr 11.

6.

Drug lag '80: the missing medicines.

Rhein RW Jr.

Med World News. 1980 Sep 1;21(18):31-48. No abstract available.

PMID:
10317008
7.

A landmark report on improving medicines for children.

't Jong GW, Klassen TP, MacLeod SM.

JAMA Pediatr. 2015 Mar;169(3):204-5. doi: 10.1001/jamapediatrics.2014.3057. No abstract available.

PMID:
25561323
8.

The morally uncomfortable global drug gap.

Cohen-Kohler JC.

Clin Pharmacol Ther. 2007 Nov;82(5):610-4. Epub 2007 Sep 26.

PMID:
17898710
9.

[Study of access to health care and drugs in Cameroon: 1. Methods and validation].

Commeyras C, Ndo JR, Merabet O, Koné H, Rakotondrabé FP.

Sante. 2005 Jul-Sep;15(3):161-6. French.

10.

What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?

Wonder M.

Expert Rev Pharmacoecon Outcomes Res. 2014 Aug;14(4):465-7. doi: 10.1586/14737167.2014.917966. Epub 2014 May 12.

PMID:
24820934
11.

The status of paediatric medicines initiatives around the world--What has happened and what has not?

Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns GL, Nakamura H, Peterson RG, Sri Ranganathan S, de Wildt SN.

Eur J Clin Pharmacol. 2012 Jan;68(1):1-10. doi: 10.1007/s00228-011-1089-1. Epub 2011 Jul 6. Review.

PMID:
21732178
12.
14.

Implications of bilateral free trade agreements on access to medicines.

Correa CM.

Bull World Health Organ. 2006 May;84(5):399-404. Epub 2006 May 17.

15.

Drug shortage crisis resolution.

Duffy E.

J Pharm Pract. 2012 Dec;25(6):619-20. doi: 10.1177/0897190012460987. No abstract available.

PMID:
23222856
16.

How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.

Gleeson D, Lopert R, Reid P.

Health Policy. 2013 Oct;112(3):227-33. doi: 10.1016/j.healthpol.2013.07.021. Epub 2013 Aug 30.

17.

Access to new medicines in New Zealand compared to Australia.

Wonder M, Milne R.

N Z Med J. 2011 Nov 25;124(1346):12-28.

PMID:
22143849
18.

Access to medicines in Senegal: results of a sample survey.

Garenne M, Candau D, Guimier JM, Badiane M, Diop AC, Teulières LC.

Trop Doct. 2006 Jan;36(1):5-8.

PMID:
16483417
19.

Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.

Kirschenbaum BE.

Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S13-20. doi: 10.2146/ajhp090462.

PMID:
19966075

Supplemental Content

Support Center